Welcome to Biocare Diagnostics Ltd.
Professional IVD Manufacturer
Supply high sensitivity and specificity
Quality diagnostics reagents at reasonable price
|
Products
Biocare Diagnostics Ltd manufacture lateral flow tests, immunoassay kits for infectious diseases, tumor marker, cardiac marker and drugs of abuse. We also supply monoclonal antibody, antigens for industrial use, all these materials used in our rapid tests and ELISA kits, it works for IVD purpose. |
||
| 1. Lateral Flow Tests | ||
| 2. ELISA Kits | ||
| product list and details listed below |
||
| Some best selling lateral flow test kits introduction | Click product name for more details | |
| 1. Rotavirus Dipstick and Cassette Rotavirus is the primary causative agent of acute gastro-enteritis, especially in children less than 2 years old. Its discovery in 1973 and its association with infantile gastro-enteritis represented a very important advance in the study of gastro-enteritis not caused by acute bacterial infection. Rotavirus is transmitted by oral-faecal contact with an incubation period of 1-3 days etc. In the case of hospitalised children with acute enteritis, up to 50 % of the samples examined are rotavirus positive High performance: --High Sensitivity: 97.6% --High Specificity: 99.3% --Ease-to-use |
 |
|
 |
||
| 2. Adenovirus Dipstick and Cassette Adenovirus is the second most common cause of viral gastro-enteritis in children (10-15%). This virus may also cause respiratory diseases and, depending on the serotype, also diarrhoea, conjunctivitis, cystitis,etc. At least 47 serotypes of adenovirus have been described, all sharing a common hexon antigen.Serotypes 40 and 41 are the ones associated with gastro-enteritis, whose main symptom is diarrhoea thatmay last between 9 and 12 days associated with temperature and vomits. High performance: --High Sensitivity: 96% --High Specificity: 98% --Ease-to-use |
 |
|
| 3. Rota/adeno Combi-- Dipstick and Cassette Rota-Adeno is a rapid, qualitative, chromatographic immunoassay which simultaneously detects rotaviruses and adenoviruses in stool samples. Rotaviruses and adenoviruses are responsible for the majority of pediatric diarrhea cases. Rapid diagnosis of viral diarrhea enables: 1) Immediate administration of appropriate therapy;
For adenovirus --Ease-to-use, Reliable results |
 |
|
 |
||
| 4. H pylori Stool Antigen Dipstick and Cassette Helicobacter pylori is a gram-negative, microaerophilic bacterium that inhabits various areas of the stomach and duodenum. It causes a chronic low-level inflammation of the stomach lining and is strongly linked to the development of duodenal and gastric ulcers and stomach cancer. Over 80% of individuals infected with the bacterium are asymptomatic. More than 50% of the world's population harbour H. pylori in their upper gastrointestinal tract. Infection is more prevalent in developing countries. The route of transmission is unknown, although individuals become infected in childhood. H. pylori's helix shape (from which the generic name is derived) is thought to have evolved to penetrate the mucoid lining of the stomach. Most individuals with chronic H. pylori infection have no symptoms. Some individuals develop more serious problems, including stomach or duodenal ulcers. Ulcers can cause a variety of symptoms or no symptoms at all. Common complaints include pain or discomfort (usually in the upper abdomen), bloating, feeling full after eating a small amount of food, lack of appetite, nausea, vomiting, and dark or tar-colored stools. Ulcers that bleed can cause a low blood count and fatigue. High performance: --High Sensitivity: 95% --High Specificity: 94% --Ease-to-use --Reliable results |
 |
|
| 5. Strep A -- Dipstick and Cassette S. pyogenes, also known as Group A Streptococcus (GAS), is the causative agent in Group A streptococcal infections, including streptococcal pharyngitis ("strep throat"), acute rheumatic fever, scarlet fever, acute glomerulonephritis and necrotizing fasciitis. If strep throat is not treated, it can develop into rheumatic fever, a disease that affects the joints and heart valves. Other Streptococcus species may also possess the Group A antigen, but human infections by non-S. pyogenes GAS strains (some S. dysgalactiae subsp. equisimilis and S. anginosus Group strains) appear to be uncommon. Group A Strep infection is generally diagnosed with a Rapid Strep Test or by culture. Streptococcus pyogenes is a spherical gram-positive bacteria that grows in long chains and is the cause of Group A streptococcal infections. S. pyogenes displays streptococcal group A antigen on its cell wall. S. pyogenes typically produces large zones of beta-hemolysis (the complete disruption of erythrocytes and the release of hemoglobin) when cultured on blood agar plates and are therefore also called Group A (beta-hemolytic) Streptococcus (abbreviated GAS). Streptococci are catalase-negative. In ideal conditions, S. pyogenes has an incubation period of approximately 10 days. |
 |
|
Enteric Diseases
| Product Code. | Product name | Sample | Package size |
| AN1002C | Rotavirus Rapid Test Cassette, Rota Cassette | feces( stool ) | 25T |
| AN1002S | Rotavirus Rapid Test Dipstick, Rota Stick | feces | 25T |
| AN1003C | Adenovirus Rapid Test Cassette, Adeno Cassette | feces | 25T |
| AN1003S | Adenovirus Rapid Test Dipstick, Adeno Stick | feces | 25T |
| AN1004C | Rota/adeno Combo Cassette | feces | 25T |
| AN1004S | Rota/adeno Dipstick | feces | 25T |
| AN1005C | EHEC Rapid Test Cassette, E. coli O157 | culture | 25T |
Fertility Tests
Infectious Diseases| Product Code. | Product name | Sample | Package size |
| ID10064 | Pregnancy Test Strip | urine | 25T |
| ID1006C | Pregancy Test Cassette, 25mIU/ml , HCG Cassette | urine | 25T |
| ID1006E | Pregnancy Test Cassettte, 10mIU/ml | urine | 25T |
| ID1006M | Pregnancy Midstream | urine | 25T |
| ID1006S | Pregnancy Test Cassette, Combo | serum/urine | 25T |
| ID1036S | Pregnancy Test Stick, HCG Sttrip | urine | 25T |
| ID1007C | Ovulation Test Cassette, LH Cassette | urine | 25T |
| ID1007S | Ovulation Stick, LH Stick | urine | 25T |
| Product Code. | Product name | Sample | Package size |
| ID1001S | HBsAg Stick | serum | 50T |
| ID1001C | HBsAg Card | serum | 50T |
| ID1010C | Anti-HCV Cassette | serum | 50T |
| ID1008C | Anti-HIV 1/2 Cassette | serum | 50T |
| AN2002C | Chlamydia Test Cassette | swab | 50T |
| AN2003C | RSV Cassette | swab | 50T |
| AN1009C | Strep A Cassette | swab | 50T |
| AN1009S | Strep A Stick | swab | 50T |
| AN1010C | H pylori stool antigen cassette and stick HpSa | stool | 50T |
Tumor Marker
| Product Code. | Product name | Sample | Package size |
| AN4001C | AFP Cassette | serum | 25T |
| AN4002C | CEA Cassette | serum | 25T |
| AN4003C | PSA Cassette | serum | 25T |
| AN4004C | Hemoglobin Cassette, Fecal Occult Blood Test | feces | 25T |
Cardiac Marker
| Product Code. | Product name | Sample | Package size |
| AN1006C | Troponin I Cassette, 0.3ng/ml | serum | 25T |
| AN1007C | Myoglobin Cassette, 80ng/ml | serum | 25T |
| AN1011C | h-FABP, 8ng/ml | plasma | 50T |
Drug of Abuse
| Product Code. | Product name | Sample | Package size |
| DA1001C | Cocaine Cassette | urine | 25T |
| DA1001S | Cocaine Stick | urine | 25T |
| DA1002C | Morphine Cassette | urine | 25T |
| DA1002S | Morphine Stick | urine | 25T |
| DA1004C | Amphetamine Cassette | urine | 25T |
| DA1004S | Amphetamine Stick | urine | 25T |
| DA1005C | THC Cassette | urine | 25T |
ELISA Kits
| 1. HBsAg ELISA Kit HBsAg is one of the earliest markers that appear in the blood following infection with Hepatitis B virus (HBV). This infection of the liver is transmitted by homosexual or heterosexual activity, blood borne exposure, mother - infant, close personal contact and by intake of contaminated water and food products. In the HBV infected people, the virus persists for the rest of their lives and can be passed on to others. Therefore Hepatitis B has become a global public health problem. Infection with HBV results in the appearance of a number of serological markers and one of the first of such markers is Hepatitis B surface antigen (HBsAg). The HBV infection causes a wide variety of liver damages such as acute self-limiting infection, fulminating hepatitis, chronic hepatitis with progression to cirrhosis and liver failure, and a symptomatic chronic carrier state. Hepatitis B surface antigen (HBsAg) appears 1-7 weeks before biochemical evidence of liver disease or jaundice. Three weeks after the onset of acute hepatitis almost half of the patients will still be positive for HBsAg. In the chronic carrier state, the HBsAg persists for long periods (6-12 months) with no seroconversion to the corresponding antibodies. Therefore, screening for HBsAg is highly desirable for all donors, pregnant women and people in high-risk groups. The HBsAg EIA is a solid-phase simultaneous sandwich immunoassay, which employs monoclonal antibodies and polyclonal antibodies specific for HBsAg. Microtiter well are coated with monoclonal antibodies specific for HBsAg. A serum specimen is added to the antibody coated Microtiter wells together with enzyme conjugated polyclonal antibodies. HBsAg, if present, will form an antibody-HBsAg-antibody-enzyme complex. The plate is then washed to remove unbound material. Finally, a solution of substrate is added to the wells and incubated. A blue color will develop in proportion to the amount of HBsAg present in the specimen. The enzyme-substrate reaction can be stopped and the result is visualized by naked eye or read by EIA plate reader for absorbance at the wavelength of 450 nm. |
| 2. Anti-HCV ELISA Kit Hepatitis C virus (HCV), which was formerly described as the parenterally transmitted form of non-A, non-B hepatitis (NANBH)1, becomes a chronic disease in 50% of the cases.2 HCV can also be transmitted through intravenous drug abuse, sexual , and household contact.3 Hepatitis C virus is a single stranded RNA virus with some structural relations to the flavivirus family. Nucleic acid sequences of HCV cDNA clones provided the basis for the construction of recombinant peptides representing putative hepatitis C virus proteins.4,5 Anti-hepatitis C virus antibody screening of blood using synthetic or recombinant proteins, helped to identify apparently healthy blood donors with anti-HCV antibodies who otherwise might have transmitted the virus.6 This is an enzyme linked immunosorbent assay using recombinant proteins derived from core regions of HCV virus to detect the presence of HCV antibodies in human sera. Multiple epitopes of HCV proteins(Core, NS3, NS4 and NS5) are bound to the microtiter wells. When antibodies to HCV are present in the test sample, they react with recombinant proteins and attach to the solid-phase. Non-reactive antibodies are removed with the wash buffer. Human IgGs bound to the antigen are reacted with goat-anti-human IgG peroxidase conjugate and visualized by subsequent reactions with a chromogenic substrate. Positive sample generates a medium to dark blue color. No color or very pale blue color indicates a negative reaction. The intensity of the reaction is photometrically quantitated. |
| 3. Anti-HIV 1/2 ELISA Kit This EIA kit is the third generation double antigen sandwich method for the detection of circulating antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and/or Human Immunodeficiency Virus Type 2 (HIV-2) in Human serum or plasma and is indicated as a screening test for serum or plasma and as an aid in the diagnosis of potential infection with HIV-1 and/or HIV-2. Human Immunodeficiency Virus Type (HIV-1) has been isolated from patients with AIDS and AIDS-related complex (ARC). HIV-1 was thought to be the sole causive agent of these syndromes until 1986, when a second type of Human Immunodeficiency Virus (HIV-2) was isolated and also reported to cause AIDS. Since the initial discovery, more than 600 cases of HIV-2 infection have been documented worldwide, with over 40 cases of AIDS related to HIV-2. Both viruses have the same morphology and lymphotropism, and the modes of transmission appear to be identical. In addition, HIV-1 and HIV-2 genomes exhibit about 60% homology in conserved genes such as gag and pol. Serologic studies have also shown that the core proteins of HIV-1 and HIV-2 display frequent cross-reactivity whereas the envelope proteins are more type-specific. Despite this immunologic cross-reactivity, detection of antibodies to HIV-2 with any of the licensed HIV-1 enzyme immunoassays is highly variable. This HIV-1/HIV-2 EIA was developed to detect antibodies to HIV-1 and /or HIV-2, for blood screening and diagnostic purposes. Any specimen that reacts in an initial test with the HIV-1/HIV-2 EIA must be retested in duplicate with the other company’s HIV-1/HIV-2 EIA. Repeatably reactive specimens may contain antibodies to either HIV-1 or HIV-2. Therefore, additional, more specific or supplemental tests for antibodies to both HIV-1 and HIV-2 such as immunoblot, immunofluorescence, radioimmuno-precipitation must be performed to verify presence of antibodies to HIV. The HIV-1/HIV-2 EIA utilizes a detection system where microplate wells are coated with synthetic peptides and recombinant antigen corresponding to a highly antigenic segment of HIV-1/HIV-2 envelope and core proteins. Serum or plasma specimens, controls are added to the wells. During incubation, antibodies specific for HIV-1 and HIV-2 present in the specimen will bind to the peptides and recombinant antigen fixed onto the microplate wells. The wells are washed to remove unbound materials, and recombinant antigen conjugate will bind to the antigen-antibody complex and excess unbound enzyme conjugates are again removed by washing. The enzyme substrate, tetramethylbenzidine (TMB), is added upon incubation the substrate will be hydrolyzed by the bound enzyme and a blue or blue-green colour develops in wells containing HIV-1 and/or HIV-2 specific antibodies. The enzyme reaction is stopped by the addition of sulphuric acid. The intensity of colour developed is read spectrophotometrically at 450nm and is proportional to the amount of antibodies present in the specimen. |
| 4. HIV Ab/Ag ELISA Kit, the 4th generation HIV kits with short window period. Human Immunodeficiency Virus Type (HIV-1) has been isolated from patients with AIDS and AIDS-related complex (ARC). HIV-1 was thought to be the sole causive agent of these syndromes until 1986, when a second type of Human Immunodeficiency Virus (HIV-2) was isolated and also reported to cause AIDS. Since the initial discovery, more than 600 cases of HIV-2 infection have been documented worldwide, with over 40 cases of AIDS related to HIV-2. Both viruses have the same morphology and lymphotropism, and the modes of transmission appear to be identical. In addition, HIV-1 and HIV-2 genomes exhibit about 60% homology in conserved genes such as gag and pol. Serologic studies have also shown that the core proteins of HIV-1 and HIV-2 display frequent cross-reactivity whereas the envelope proteins are more type-specific. Despite this immunologic cross-reactivity, detection of antibodies to HIV-2 with any of the licensed HIV-1 enzyme immunoassays is highly variable. This HIV-1/HIV-2 EIA was developed to detect antibodies to HIV-1 and /or HIV-2, for blood screening and diagnostic purposes. Any specimen that reacts in an initial test with the HIV-1/HIV-2 EIA must be retested in duplicate with the other company's HIV-1/HIV-2 EIA. Repeatably reactive specimens may contain antibodies to either HIV-1 or HIV-2. Therefore, additional, more specific or supplemental tests for antibodies to both HIV-1 and HIV-2 such as immunoblot, immunofluorescence, radioimmuno-precipitation must be performed to verify presence of antibodies to HIV. The HIV-1/HIV-2 Ab/Ag EIA utilizes a detection system where microplate wells are coated with synthetic peptides and recombinant antigen corresponding to a highly antigenic segment of HIV-1/HIV-2 envelope and core proteins and anti-p24 antibody. Serum or plasma specimens, controls are added to the wells and then add biotin-anti-p24. During incubation, antibodies specific for HIV-1 and HIV-2 present in the specimen will bind to the peptides and recombinant antigen fixed onto the microplate wells and p24 will be captured by anti-p24 on the microplate wells and also binding with biotin-anti-24. The wells are washed to remove unbound materials, and the conjugate will bind to the antigen-antibody complex and excess unbound enzyme conjugates are again removed by washing. The enzyme substrate, tetramethylbenzidine (TMB), is added upon incubation the substrate will be hydrolyzed by the bound enzyme and a blue or blue-green colour develops in wells containing HIV-1 and/or HIV-2 specific antibodies and/or p24 antigen. The enzyme reaction is stopped by the addition of sulphuric acid. The intensity of colour developed is read spectrophotometrically at 450nm and is proportional to the amount of antibodies present in the specimen. |
| 5. Anti-HAV IgM ELISA Kit Hepatitis A continues to be one of the most frequently reported vaccine-preventable diseases in the world, despite the licensure of hepatitis A vaccine in 1995. Widespread vaccination of appropriate susceptible populations would substantially lower disease incidence and potentially eliminate indigenous transmission of hepatitis A virus (HAV) infection. HAV, a 27-nm RNA agent classified as a picornavirus, can produce either asymptomatic or symptomatic infection in humans after an average incubation period of 28 days (range, 15-50 days). The illness caused by HAV infection typically has an abrupt onset of symptoms that can include fever, malaise, anorexia, nausea, abdominal discomfort, dark urine, and jaundice. The likelihood of having symptoms with HAV infection is related to the person's age. In children less than 6 years of age, most (70%) infections are asymptomatic; if illness does occur, it is not usually accompanied by jaundice. Among older children and adults, infection is usually symptomatic, with jaundice occurring in greater than 70% of patients. Signs and symptoms usually last less than 2 months, although 10%-15% of symptomatic persons have prolonged or relapsing disease lasting up to 6 months. In infected persons, HAV replicates in the liver, is excreted in bile, and is shed in the stool. Peak infectivity of infected persons occurs during the 2-week period before onset of jaundice or elevation of liver enzymes, when the concentration of virus in stool is highest. The concentration of virus in stool declines after jaundice appears. Children and infants can shed HAV for longer periods than adults, up to several months after the onset of clinical illness. Chronic shedding of HAV in feces does not occur; however, shedding can occur in persons who have relapsing illness. Viremia occurs soon after infection and persists through the period of liver enzyme elevation. Hepatitis A cannot be differentiated from other types of viral hepatitis on the basis of clinical or epidemiologic features alone. Serologic testing to detect immunoglobulin M (IgM) antibody to the capsid proteins of HAV (IgM anti-HAV) is required to confirm a diagnosis of acute HAV infection. In most persons, IgM anti-HAV becomes detectable 5-10 days before the onset of symptoms and can persist for up to 6 months after infection. Immunoglobulin G (IgG) anti-HAV, which appears early in the course of infection, remains detectable for the person's lifetime and confers lifelong protection against the disease. Commercial diagnostic tests are available for the detection of IgM and total (IgM and IgG) anti-HAV in serum. HAV RNA can be detected in the blood and stool of most persons during the acute phase of infection by using nucleic acid amplification methods, and nucleic acid sequencing has been used to determine the relatedness of HAV isolates. HAV infection is acquired primarily by the fecal-oral route by either person-to-person contact or ingestion of contaminated food or water. On rare occasions, HAV infection has been transmitted by transfusion of blood or blood products collected from donors during the viremic phase of their infection. In experimentally infected nonhuman primates, HAV has been detected in saliva during the incubation period; however, transmission by saliva has not been demonstrated. Depending on conditions, HAV can be stable in the environment for months. Heating foods at temperatures greater than 185 F (85ºC) for 1 minute or disinfecting surfaces with a 1:100 dilution of sodium hypochlorite (i.e.,household bleach) in tap water is necessary to inactivate HAV. Because most children have asymptomatic or unrecognized infections, they play an important role in HAV transmission and serve as a source of infection for others. In one study of adults without an identified source of infection, 52% of their households included a child less than 6 years old, and the presence of a young child was associated with HAV transmission within the household. In studies where serologic testing of the household contacts of adults without an identified source of infection was performed, 25%-40% of the contacts less than 6 years old had serologic evidence of acute HAV infection (IgM anti-HAV). The assay is based on the principle of "IgM capture" where IgM class antibodies in the sample are first captured by the solid phase coated with anti hIgM antibody. After washing out all the other components of the sample and in particular IgG antibodies, the specific IgM captured on the solid phase are detected by the addition of a purified preparation of HAV Ag, labelled with a monoclonal antibody conjugated with peroxidase (HRP). After incubation, microwells are washed to remove unbound conjugate and then the chromogen/substrate is added. In the presence of peroxidase the colourless substrate is hydrolysed to a coloured end-product, whose optical density may be detected and is proportional to the amount of IgM antibodies to HAV present in the sample. |
| 6. Anti-HEV IgM ELISA Kit Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Hepatitis E Virus in human plasma and sera.The kit may be used for the follow-up of HEV-infected patients. Major epidemics of enterically transmitted non-A, non-B hepatitis (ET-NANBH) have been found to occur in developing regions such as Asia, the former USSR, Central America and Africa (1,2). Sporadic cases have also been reported in developed nations, including Australia, the United Kingdom and the United States (3,4,5). Cases in developed nations have generally been associated with travel to endemic regions. The course of the infection is generally acute and self-limiting without chronic sequelae. There is, however, a high incidence of mortality in pregnant women in the third trimester, about 10-20% (1) and a mortality rate of 1-2% in the general population, which is 10 times that of hepatitis A (HAV). With the cloning of the etiological agent of ET-NANBH and the identification of type common viral epitopes (6,7), specific diagnostic tools have been developed to detect antibodies to hepatitis E virus (HEV). Studies with Egyptian children from Benha in 1986 revealed that previous exposure to HEV will elicit an IgG response (8) which may be transient and disappear in 6 months but can sometimes last up to 8 years or more as seen in a recent study in Taiwan (9). The IgM response has been shown to be limited to the acute phase of HEV infection. Previously, detection of the acute response in HEV infection has been through observation of viral particles in the stool of infected individuals using IEM or by PCR (10, 11). This method requires expensive equipment and technique-dependent expertise. Furthermore, the shedding of the viral particles is usually in small quantities and may not be of sufficient titer to be detected. These tests are based on synthetic immunodominant antigens derived from conservative regions of the virus. Tests for IgM are used to determine the nature of the infective agent in patients showing symptoms of hepatitis, in order to rule out the possibility of other most severe viral infections (HBV, HDV, HCV). The assay is based on the principle of "IgM capture" where IgM class antibodies in the sample are first captured by the solid phase coated with anti hIgM antibody. After washing out all the other components of the sample and in particular IgG antibodies, the specific IgM captured on the solid phase are detected by the addition of a purified preparation of HEV Ag conjugated with peroxidase (HRP). After incubation, microwells are washed to remove unbound conjugate and then the chromogen/substrate is added. In the presence of peroxidase the colourless substrate is hydrolysed to a coloured end-product, whose optical density may be detected and is proportional to the amount of IgM antibodies to HEV present in the sample. |
| Blood Donor Screening | ||||
| Product Code | Product Description | Specimen | Package Size | Sensitivity |
| CT1001B | HBsAg ELISA Kit | serum | 96tests/kit | 0.5ng/ml |
| CT1001C | HBsAg ELISA Kit | serum | 480tests/kit | 0.5ng/ml |
| CT3001B | Anti-HCV ELISA Kit | serum | 96tests/kit | 2NCU/ml |
| CT3001C | Anti-HCV ELISA Kit | serum | 480tests/kit | 2NCU/ml |
| CT4001B | Anti-HIV 1/2 ELISA Kit | serum | 96tests/kit | 2NCU/ml |
| CT4001C | Anti-HIV 1/2 ELISA Kit | serum | 480tests/kit | 2NCU/ml |
| CT4001G | HIV Ab/Ag ELISA KIt(4th generation) | serum | 96tests/kit | |
| CT6001B | Anti-TP ELISA Kit | serum | 96tests/kit | 2NCU/ml |
Infectious Disease
| Product Code | Product Description | Specimen | Package Size | Method |
| CT1001B | HBsAg ELISA Kit | serum | 96tests/kit | Sandwich |
| CT1002B | Anti-HBsAg ELISA Kit | serum | 96tests/kit | Sandwich |
| CT1003B | HBeAg ELISA Kit | serum | 96tests/kit | Sandwich |
| CT1004B | Anti-HBeAg ELISA Kit | serum | 96tests/kit | Competitive |
| CT1005B | Anti-HBc total ELISA Kit | serum | 96tests/kit | Competitive |
| CT1006B | Anti-HBc IgM ELISA Kit | serum | 96tests/kit | Capture |
| CT2001M | Anti-HAV IgM ELISA Kit | serum | 96tests/kit | Capture |
| CT2001G | Anti-HAV IgG ELISA Kit | serum | 96tests/kit | Indirect |
| CT2001T | Anti-HAV total ELISA Kit | serum | 96tests/kit | Competitive |
| CT3001B | Anti-HCV ELISA Kit | serum | 96tests/kit | Indirect |
| CT4001B | Anti-HIV 1+2 ELISA Kit | serum | 96tests/kit | Sandwich |
| CT4001G | HIV Ab/Ag ELISA Kit | serum | 96tests/kit | Sandwich |
| CT5001M | Anti-HEV IgM ELISA Kit | serum | 96tests/kit | Capture |
| CT5001G | Anti-HEV IgG ELISA Kit | serum | 96tests/kit | Indirect |
| CT5001T | Anti-HEV total ELISA Kit | serum | 96tests/kit | Sandwich |
| TB1001B | Anti-TB IgG ELISA Kit | serum | 96tests/kit | Indirect |
| HP1001B | Anti-H pylori IgG ELISA Kit | serum | 96tests/kit | Indirect |
| CT6001B | Anti-TP ELISA Kit | serum | 96tests/kit | Sandwich |
| CT9001B | Rotavirus ELISA Kit | feces | 96tests/kit | Sandwich |
| CT9002B | Adenovirus ELISA Kit | feces | 96tests/kit | Sandwich |
Tumor
Marker
| Product Code | Product Description | Specimen | Sensitivity | Package Size |
| CT3002B | AFP ELISA Kit | serum | 25ng/ml | 96tests/kit |
| CT3003B | CEA ELISA Kit | serum | 5ng/ml | 96tests/kit |
| CT3004B | PSA ELISA Kit | serum | 4ng/ml | 96tests/kit |
| CT3005B | beta-HCG ELISA Kit | serum | 25mIU/ml | 96tests/kit |